A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors

被引：0
|
作者：
Pelster, Meredith
Torre, Marcio
Kannan, Geoffrey Sumithran
Gargano, Michele Anne
Mattson, Paulette
Rathmann, Blaine
Bose, Nandita
Iglesias, Jose Luis
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] HiberCell Inc, New York, NY USA
[3] Labcorp, Burlington, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3179
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
    Moore, Kathleen N.
    Sabanathan, Dhanusha
    Du, Yiqun
    Duan, Huaxin
    Li, Xiumin
    Wang, Feng
    Marathe, Omkar
    Yang, Hua
    Makker, Vicky
    Growdon, Whitfield
    Coward, Jim
    Zhao, Peng
    Liu, Liming
    Shi, Rong
    Liu, Shengxue
    Gu, Wei
    Qiu, Yang
    Zhu, Zhongyuan
    Zhang, Jian
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors
    Italiano, Antoine
    Isambert, Nicolas
    Metges, Jean-Philippe
    Toulmonde, Maud
    Cousin, Sophie
    Pernot, Simon
    Spalato, Mariella
    Grellety, Thomas
    Auzanneau, Celine
    Lortal, Barbara
    Kind, Michele
    Le Loarer, Francoid
    Sellan-Albert, Sabrina
    Bellera, Carine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors
    Wang, Jiayu
    Wang, Wenna
    Tong, Zhongsheng
    Shi, Yehui
    Shi, Yanxia
    Zheng, Qiufan
    Yu, Shunjiang
    Cao, Yuanyuan
    Xie, Ning
    Fan, Jianru
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma
    McKean, Meredith
    Aggen, David Henry
    Lakhani, Nehal J.
    Bashir, Babar
    Luke, Jason J.
    Hoffman-Censits, Jean H.
    Alhalabi, Omar
    Bowman, Isaac Alex
    Guancial, Elizabeth A.
    Tan, Alan
    Lingaraj, Trupti
    Timothy, Marissa
    Kacena, Katherine
    Malek, Karim S.
    Santillana, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
    Goel, Sanjay
    Swami, Umang
    Kumar, Kirushna
    Dittrich, Christian
    Reyderman, Larisa
    Jain, Minish
    Aisner, Joseph
    Song, James
    Petrylak, Daniel P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 567 - 578
  • [26] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.
    Krebs, Matthew
    Johnson, Melissa Lynne
    Cho, Byoung Chul
    Park, Keunchil
    Haddish-Berhane, Nahor
    Zemlickis, Donna
    Mitselos, Anna
    Meacle, Francis
    Knoblauch, Roland Elmar
    Hellemans, Peter
    Minchom, Anna Rachel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
    Sanjay Goel
    Umang Swami
    Kirushna Kumar
    Christian Dittrich
    Larisa Reyderman
    Minish Jain
    Joseph Aisner
    James Song
    Daniel P. Petrylak
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 567 - 578
  • [28] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Bendell, Johanna C.
    Hong, David S.
    Burris, Howard A., III
    Naing, Aung
    Jones, Suzanne F.
    Falchook, Gerald
    Bricmont, Patricia
    Elekes, Agnes
    Rock, Edwin P.
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 125 - 130
  • [29] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Johanna C. Bendell
    David S. Hong
    Howard A. Burris
    Aung Naing
    Suzanne F. Jones
    Gerald Falchook
    Patricia Bricmont
    Agnes Elekes
    Edwin P. Rock
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 125 - 130
  • [30] A phase 1b, open-label, dose escalation and expansion study of demcizumab plus pembrolizumab in patients with locally advanced or metastatic solid tumors
    Johnson, Melissa
    Rasco, Drew
    Schneider, Brian
    Shu, Catherine
    Jotte, Robert
    Parmer, Hema
    Stagg, Robert
    Lopez, Juanita
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345